Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification by G. Gasparini (7127321) et al.
 
 
 
This item was submitted to Loughborough’s Institutional Repository by the 
author and is made available under the following Creative Commons Licence 
conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
 1
Preparation and characterization of PLGA particles for 
subcutaneous controlled drug release by membrane emulsification 
 
 
G. Gasparinia, S.R. Kosvintsevb, M.T. Stillwella, and R.G. Holdicha,* 
 
aDepartment of Chemical Engineering, Loughborough University,  
Leicestershire, LE11 3TU, UK. 
bMicropore Technologies Ltd., The Innovation Centre, Epinal Way, Loughborough, 
Leicestershire, LE11 3EH, UK. 
 
 
*corresponding author:  Tel: +44 1509 222519;  
fax: +44 1509 223923; 
E-mail: R.G.Holdich@Lboro.ac.uk 
 2
Abstract 
Uniformly sized microparticles of poly(DL, lactic-co-glycolic) (PLGA) acid, with controllable 
median diameters within the size range 40 to 140 microns, were successfully prepared by 
membrane emulsification of an oil phase injected into an aqueous phase, followed by solvent 
removal. Initially, simple particles were produced as an oil-in-water emulsion, where 
dichloromethane (DCM) and PLGA were the oil phase and water with stabiliser was the 
continuous phase. The oil was injected into the aqueous phase through an array type 
microporous membrane, which has very regular pores equally spaced apart, and two different 
pore sizes were used: 20 and 40 microns in diameter. Shear was provided at the membrane 
surface, causing the drops to detach, by a simple paddle stirrer rotating above the membrane. 
Further tests involved the production of a primary water-in-oil emulsion, using a mechanical 
homogeniser, which was then subsequently injected into a water phase through the 
microporous membrane to form a water-in-oil-in-water emulsion. These tests used a water 
soluble model drug (blue dextran) and encapsulation efficiencies of up to 100% were obtained 
for concentrations of 15% PLGA dissolved in the DCM and injected through a 40 micron 
membrane.  
 
Solidification of the PLGA particles followed by removal of the DCM through the surrounding 
aqueous continuous phase. Different PLGA concentrations, particle size and osmotic 
pressures were considered in order to find their effect on encapsulation efficiency. Osmotic 
pressure was varied by changing the salt concentration in the external aqueous phase whilst 
maintaining a constant internal aqueous phase salt concentration. Osmotic pressure was 
found to be a significant factor on the resulting particle structure, for the tests conducted at 
lower PLGA concentrations (10 and 5% PLGA). The PLGA concentration and particle size 
distribution influence the time to complete the solidification stage and a slow solidification, 
formed by stirring gently overnight, provided the most monosized particles and highest 
encapsulation efficiency.  
 
Keywords 
PLGA 
Membrane emulsification 
Microparticle 
Osmotic pressure 
Encapsulation efficiency 
 3
Contents of paper 
 
p. 4  Introduction 
p. 5  Materials and Method 
p. 6   1. Simple Particle Production 
p. 7   2. Encapsulated Particle Production 
p. 8   Particle Size and Encapsulation Efficiency Analysis 
p. 8  Results and Discussion 
p. 8   Simple Particle Production-Droplet Formation 
p. 9   Simple Particle Production-Solidification Stage 
p. 9   Encapsulated Particle Production 
p. 11   Encapsulation Efficiency 
p. 13  Conclusions 
p. 16  References 
p. 19  List of Tables 
p. 23  List of Figures 
 
  
 
 4
Introduction 
Controlled release drug encapsulation is one of the leading research fields in the 
pharmaceutical industry [1]. For treatments that require repeated administration, via ingestion 
or injection, and for compounds such as proteins with very short half life, the possibility of a 
single administration followed by a slow and controllable release is an improvement on the 
usual forms of drug delivery. A vast range of biopolymers have been considered, and the use 
of different biopolymer combination has been considered, [2–12]. Once the biopolymer enters 
the body, the environmental conditions cause it to degrade in a predictable manner into 
monomers that are already present in the body, hence the biocompatibility. This degradation 
can be controlled through the polymer composition and the characteristics of the 
administration, to gradually release the encapsulated drugs. 
 
 This study considers poly(D,L-lactic-co-glycolic) acid (PLGA), a biopolymer approved by the 
Food and Drug Administration for human use [13]. By changing the lactic/glycolic acid ratio of 
the PLGA molecules it is possible to control the degradation rate. PLGA has been used to 
prepare tablets to be ingested, scaffolds, nanoparticles for inhalers or intravenous injections 
and microparticles for subcutaneous depot [4–7,9,12,14–17]. The work reported here 
produced particles in the range of 40 to 140 µm via membrane emulsification followed by the 
solvent removal method to produce the PLGA microspheres. 
 
The first step is to produce an emulsion where PLGA is dissolved in an organic solvent and 
dispersed as droplets in a aqueous continuous phase. Then the organic solvent is removed 
by evaporation and the PLGA solidifies to form particles containing the drug in its matrix. 
Hydrophobic drugs are easily dissolved together with the PLGA in the organic solvent, while 
hydrophilic drugs would be poorly encapsulated with this method. For hydrophilic drugs a 
double emulsion is required: firstly the drug is dissolved in an aqueous phase and dispersed 
in PLGA and organic solvent. Subsequently, the organic phase is dispersed again into a 
second water phase giving a Water-Oil-Water (W/O/W) dispersion. With this method both 
hydrophobic and hydrophilic drugs can be successfully encapsulated [4,5,9,18,19].  
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There are many membrane emulsification techniques available, but most are appropriate for 
the production of fine drops, less than 20 microns, and the intention of the project was to 
produce particles significantly bigger than this. Recently, a membrane technique operating in 
the required size range has been detailed [20,21].  The Micropore Technologies Ltd 
Dispersion Cell provides the ability to tailor the droplet size and size distribution, by changing 
operating conditions and the chemical properties of the phases. The ability to make 
dispersions of a known, and controlled, size distribution is important for controlled release 
drug encapsulated particles as knowing the exact size of the particles facilitates modelling the 
drug release and controls aspects such as the initial burst. The latter effect could lead to 
problematic side effects. The Dispersion Cell technique minimises the shear, and other 
operating conditions, experienced by the drugs, which may be perishable. This reduces 
losses in encapsulation efficiency that may occur when not operating under such mild 
operating conditions. This work presents operating parameters involved in the stages of 
emulsion production and particle solidification. Droplet and particle size, size distributions and 
the encapsulation efficiency of a water soluble model drug are reported. 
 
Materials and Methods 
The method selected to produce the PLGA particles is membrane emulsification followed by 
solvent evaporation. Both simple PLGA particles and an encapsulated water-soluble model 
drug were investigated. Initially, the simple particles were created to test the conditions 
needed to produce particles in the desired size range. It is unlikely that these conditions 
would change significantly in the case of dissolving a hydrophobic drug in the PLGA oil 
phase. For a hydrophilic drug encapsulation is required, in which the water soluble drug is 
encapsulated by the oil phase, which is then dispersed in to water to form a W/O/W emulsion. 
The latter process is significantly more technically demanding than forming a O/W emulsion, 
as it is important that the primary emulsion does not break during the process of secondary 
emulsion formation. In both sets of tests the chemicals used were: Resomer RG 503H (d,l-
lactide glicolide ratio 50/50) obtained from Boehringer Ingelheim, Poly Vinyl Alcohol (PVA MW 
25000, 88% degree of hydrolysis) and sodium chloride came from Fisher Scientific, Di-
ChloroMethane (DCM) from Acros and blue dextran 2000 from Pharmacia Fine Chemicals. 
Reverse osmosis water was obtained from a Millipore RO unit. The membrane emulsification 
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apparatus, a stirred Dispersion Cell, was provided by Micropore Technologies Ltd., 
Leicestershire, UK. In the Dispersion Cell the discontinuous phase is injected at the base of 
the cell, where it passes through the membrane, and the droplets emerge into the continuous 
phase. The continuous phase is agitated by a simple two-bladed paddle controlled by a DC 
motor. The membrane is a thin flat metal disc with monosized circular pores distributed in a 
highly regular array and is chemically treated in order to make the surface hydrophilic, see 
Figure 1. Extensive validation of the Dispersion Cell as a means to provide reproducible drop 
sizes was performed in the work described previously [20,21], using the system of sunflower 
oil injected in to water, where multiple sets of experiments were performed for each reaction 
condition tested. A similar set of experiments was not performed here, due to the cost of the 
materials.  
 
1. Simple Particle Production 
Table 1 summarises the composition and the operating parameters used in the following 
experiments. When simple particles are produced, 10 ml of DCM with different concentrations 
of PLGA (5, 10, 15, 20 and 30%) were injected at a rate of 0.5 ml/min into 150 ml of water 
containing 1% w/v PVA using a 40 µm pore diameter membrane. The continuous phase was 
agitated at a stirrer speed of 600 rpm and the cell was immersed in a cold bath at 4°C. Once 
the injection phase was finished, the droplets were solidified by different methods. The 
solidification is a result of the solvent (DCM) leaving the system. It is possible to influence this 
stage by controlling the diffusivity of the solvent out of the drops as they solidify to form 
particles. This control can be achieved by: temperature, surface area of the liquid free surface 
from which the DCM evaporates into the atmosphere and DCM concentration in the water 
phase. After producing the emulsion in the stirred cell it was poured into a beaker and stirred 
constantly at 120 rpm at room temperature for DCM removal. Four different solidification 
methods were tested changing evaporation areas and adding continuous phase to change 
DCM aqueous phase concentration.  
 
The four different methods investigated, and different solidification times, are shown in Table 
2. The solidification is the result of the DCM evaporation through the water phase and into the 
outside environment, so changing the DCM solubility in water controls the solidification rate. 
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In a fast solidification the emulsion (160 ml) was poured into a beaker with a free surface of 
150 cm2 together with one litre of reverse osmosis water containing 1% PVA to act as a 
stabiliser and keep the droplets-particles apart. The system was continuously stirred and the 
complete solidification process took approximately two hours. In a gradual (Grad) 
solidification 450 ml of new continuous phase was gradually added to the stirred emulsion at 
a rate of 7.5 ml/min, for one hour, followed by stirring for approximately 24 hours. In a slow 
solidification process no other phase was added, the emulsion was stirred in a beaker with a 
free surface of 50 cm2 for approximately 24 hours. In a very slow solidification process the top 
of the beaker was sealed with only the entrance for the overhead stirrer open, the 
solidification process took three days. 
 
2. Encapsulated Particle Production 
Firstly, 20 ml of reverse osmosis water, 1000 ppm of blue dextran 2000 and 40 g/l salt were 
emulsified with 50 ml of DCM and different concentrations of PLGA (5, 10 and 15%) using a 
mechanical homogenizer (Silverson Machines Ltd.), for three minutes at 8600 rpm. These 
operating conditions were established by observation using a microscope: at 8600 rpm there 
was a noticeable difference between the distribution given by homogenising for 60 and 90 
seconds, but no further difference was observable beyond this time. Hence, a total time of 
180 seconds was used to ensure uniformity of the primary emulsion between the different 
tests. The primary emulsion, formed in this way, was completely stable showing no signs of 
coalescence and did not require a surfactant for stabilisation. This primary emulsion became 
the discontinuous, or injected, phase for the secondary emulsification. For the second 
emulsification, 10 ml of the discontinuous phase was injected in the dispersion cell into 150 ml 
of reverse osmosis water containing 1% PVA and different salt concentrations (40, 33, 26, 16 
g/l). The injection rate was 0.5 ml/min, the stirrer agitation speed was either 600 or 860 rpm 
and membrane pore diameters of 40 and 20 µm respectively were used. The emulsification 
and the solidification stages were conducted at room temperature. A small amount of salt and 
water saturated in DCM was required to slow down DCM diffusion into the water during the 
emulsification. Different solidification methods were tested for the simple particles and from 
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those results, the solidification method chosen for encapsulated particles was an overnight 
stir at 120 rpm.  
 
The optimal concentration of PVA chosen for both types of experiments was 1%, determined 
from the literature, in order to provide the best particle size distribution, [22], and 
encapsulation efficiency, [23]. Blue dextran 2000 was selected as the water-soluble model 
drug because it can be easily measured spectrophotometrically and it has already been used 
as a marker when producing smaller PLGA microparticles [23]. Preparation temperature 
effects were thoroughly studied. It is reported that the emulsification temperature affects 
solvent removal rate, and therefore influences the surface morphology and the size of the 
final product, but not the encapsulation efficiency [24,25].  
 
Particle Size and Encapsulation Efficiency Analyses 
Three pictures were taken of the newly formed emulsion using sampling and analysis under 
an optical microscope. The emulsion was not stable enough to be analyzed using an 
instrumental technique, such as laser light diffraction. Up to 600 droplets were size analyzed 
using an image analysis system running Image J software. Once the solidified particles were 
obtained, their size and size distribution were measured using a Malvern Mastersizer. A 
comparison of Image J and Malvern data showed that the two methods provide very similar 
results.  
 
To determine the amount of blue dextran 2000 released, or not encapsulated, during the 
secondary emulsification process a sample from the outer water phase was filtered using 
Whatman filter paper number 3 and analyzed by an ultraviolet spectrophotometer at 620 nm 
(UV-1201 Shimadzu). 
 
Results and Discussion 
Since the method chosen is membrane emulsification followed by solvent removal, oil droplet 
and solidified particle size are closely linked. It is important to control the emulsification stage, 
and the solidification stage to achieve and maintain the required size and size distribution. 
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Other operating characteristics influence the surface morphology and hence the 
encapsulation efficiency.  
 
The Micropore Dispersion Cell has already been tested using other systems: sunflower oil in 
water [20], paraffin wax in water and water in kerosene [21]. The current challenge was to test 
the control parameters (membrane pore size, shear at the membrane surface, chemical 
properties) on the PLGA system and to preserve the size and size distribution properties 
during the solidification stages, whilst maintaining a good encapsulation efficiency. 
 
Simple Particle Production - Droplet Formation 
The effect of agitation speed on the droplet size was tested by simple particle production, i.e. 
O/W emulsions. Figure 2 presents a similar trend to those already reported, the droplet size 
decreases as the agitation speed (or shear) increases. This is due to a higher drag force at 
the membrane surface, which directly depends on the rotation speed [20]. In the previous 
work with the stirred cell it was shown that the particle size uniformity of the drops formed is a 
function of the viscosity of the dispersed phase used. In the system studied here dispersed 
phase viscosity was changed by a variation in the PLGA content within the DCM, between 5 
and 30% PLGA dissolved in DCM was used. The results are shown in Figure 3, the volume 
distribution improves with an increase in the PLGA concentration, as the width of the 
distribution curves can be seen to become narrower with increasing PLGA concentration and 
the peak height increases, hence with a higher discontinuous phase viscosity. 
 
Simple Particle Production - Solidification Stage 
After forming the drops, the next step was to maintain them during the solidification. During 
this stage, the solvent leaves the system, so particle shrinkage is to be expected. The 
droplets are very unstable and during this stage they may collide and coalesce, or be broken 
by the shear. The amount of PLGA used for these tests was 5%, in 95% DCM. As shown in 
Figure 4, all the final solidified particles are smaller than the original droplets and they all 
shrank by the same amount. The “slow” procedure produced the best particle size 
distribution, actually improving it from the 5% PLGA droplet size distribution. 
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It appeared that when the solidification time is too long, the droplets display a very long 
unstable period and their final shape is no longer spherical but elongated by the mild stirring, 
Figure 5a. All the other particles are spherical and with an orange peel surface effect, see 
Figure 5b for an example image. The solidification methods chosen did not appear to 
influence the outer surface morphology, as also obtained in [26]. In both Figure 5a and 5b 
there is a scale bar in the bottom right hand corner of the image, illustrating a distance of 100 
microns. One of the project aims was to produce micro particles with a diameter ranging from 
50 up to 100 µm and this appears to be successfully achieved for the simple PLGA particles. 
 
Encapsulated Particle Production 
In this case the aim is to encapsulate an internal aqueous phase within the PLGA oil phase in 
a W/O/W double emulsion. The primary emulsion is obtained by homogenization. Very small 
drops are required in order for them to spread evenly in the PLGA matrix. Using the 
homogenizer for three minutes produced a sufficiently small droplet size that the emulsion 
was stable during the secondary emulsification without the need for any surfactant. The 
higher the amount of PLGA, the more stable the primary emulsion became.  
 
To obtain particles of 100 µm, a 40 µm pore diameter membrane was used, and a stirrer 
agitation speed of 600 rpm. To obtain smaller particles of 50-60 µm, a membrane with a pore 
diameter of 20 µm and a higher agitation speed of 860 rpm was used. One of the main 
properties of membrane emulsification is the possibility to link droplet size to pore size and 
operating conditions, see Figure 2 and [22]. The PLGA concentration also influenced the 
particle size. Contrary to reports in the literature [23,27], an increase in PLGA concentration 
caused a decrease in particle size. This is a consistently observable trend in Figure 6 and 
may be related to the porous nature of the resulting PLGA microsphere and the swelling it 
may experience.  
 
One important aspect in the degree of uniformity of the encapsulated particles formed was the 
salt concentration used in the external aqueous phase during the secondary emulsification 
and how it relates to the salt concentration of the internal aqueous phase used in the primary 
emulsification. This influences the osmotic pressure across the oil phase, which acts as a 
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barrier between the two aqueous phases, [28]. The degree of uniformity of the size 
distribution can be measured by the ‘span’, which is defined as follows: 
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Where x90, x50 and x10 are the particle sizes at which 90, 50 and 10% of the distribution fall 
below. Hence, the nearer the value of the span to 0 the more monosized the distribution is. In 
general, a distribution is considered to be monosized if its span value is less than unity. 
 
Table 3 provides values of the span for the encapsulated particles using a variety of ratios of 
internal phase to external phase salt concentration. In the experiments the inner phase 
contained 40 g/l salt and outer/inner salt ratios used were between 1:1 (same concentration of 
salt in the inner and outer water phase) to a ratio of 1:3 (outer phase salt concentration of 13 
g/l, inner phase salt concentration of 40 g/l). Figure 6 illustrates the variation in the median 
size, based on the number distribution of the particles, as a function of the ratio of the salt 
concentration outer:inner. There is no osmotic pressure when the salt concentration is equal 
between the phases. At lower ratios it is likely that water enters the drop, which then solidifies, 
so a larger diameter particle results from the process than given by a ratio of 1:1. This effect 
is apparent for all concentrations of PLGA used in the process and for the two membrane 
pore sizes tested. 
 
Shrinkage, which occurs due to the removal of the solvent from the beads, and solidification 
of blank and encapsulated particles has been extensively studied, [29]. In the study reported 
here the intention is to consider the effect of osmotic pressure and PLGA concentration, whilst 
keeping constant the amount of inner water phase. PLGA concentration does not appear to 
affect the particle size or shrinkage, and this behaviour is characteristic of the encapsulated 
particles. For a given amount of inner water phase the same amount of shrinkage occurs 
despite the fact that the amount of PLGA is lower when a lower concentration is used. It is 
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likely that this has an influence on the structure of the PLGA matrix, which is likely to be an 
important factor in the drug release. 
 
Figure 7 illustrates the shrinkage that occurs between the as-formed drops and the final solid 
particles. Shrinkage is due to the removal of the DCM solvent, leaving the PLGA matrix and, 
in the case of the encapsulated particles, the inner water phase. As reported in [28] when the 
difference of salt concentration is high between the inner and outer phases, the osmotic 
pressure acts in order to equalize them, so for higher salt concentration in the inner phase 
water from the outer phase enters the particles, which explains why the apparent shrinkage is 
reduced at the lower salt concentration in the outer phase.  
 
Encapsulation Efficiency 
The encapsulation efficiency for the different operating conditions is shown in Figure 8. An 
encapsulation efficiency of less than 100% may be due to two effects: disruption of the 
primary W/O emulsion which is being emulsified into a W/O/W emulsion, and by the leaching 
out of material from the inner aqueous phase after the encapsulated particles have been 
formed. Forming large encapsulated particles, particle diameters bigger than approximately 
10 microns, is quite challenging as the larger drops tend to be more easily ruptured. Hence, it 
may be possible to create a W/O emulsion using a mechanical homogeniser, but the 
subsequent creation of the secondary emulsion (to form a W/O/W emulsion) is unlikely to 
have a high encapsulation efficiency if a mechanical homogeniser is again used. As the high 
shear will break the primary emulsion releasing the internal water phase. Thus, a gentle 
technique for the formation of the secondary emulsion is required, that will not give rise to 
rupture of the primary emulsion. Conventional membrane emulsification uses tortuous pore 
channel type membrane structures, which provide lower shear conditions than a mechanical 
homogeniser, but still provide significant opportunities for disruption of the primary emulsion 
which is being injected through these tortuous pore channels. The membrane used in this 
study, and illustrated in Figure 1, does not use a tortuous pore channel and provides a very 
short and gentle shear path for the primary emulsion to flow through to the surface of the 
membrane, where it is broken in a controlled manner by the shear imposed at the membrane 
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surface arising from the stirrer. Hence, very high encapsulation efficiencies can be provided, 
as illustrated in Figure 8. 
 
The second effect, leaching of the inner water phase material, may partially be influenced by 
the water transport due to osmotic gradients. When osmotic transport is high it is possible that 
pathways for transfer between the two aqueous phases (internal and external) become 
available. When 15% PLGA is used, the encapsulation efficiency does not depend on the 
osmotic pressure and it is higher for larger particles, provided by the 40 micron pore size 
membrane. Generally, a higher PLGA concentration gives a higher entrapment efficiency, 
when all the other variables are constant. When a lower PLGA concentration is used, the 
different salt concentration becomes important and the encapsulation efficiency is lower when 
less salt is used in the outer phase. This effect is very noticeable with the smaller particles, 
formed using the 20 micron pore size membrane.  
 
As described previously, [27], the particles are formed by progressive loss of the organic 
solvent, so an increase in the PLGA concentration of the oil phase leads to a shorter time 
needed for solidification. The dominating loss of inner phase is believed to be due to transport 
to the external phase, and if the unstable time is shorter, then the loss of the inner phase will 
be lower. Also, higher PLGA concentrations result in a higher viscosity of the oil phase, which 
restricts the transport of the inner phase material towards the outer phase [30]. The diffusion 
of the inner phase material is also influenced by the size of the particle [14]. These conditions 
help explain why smaller particles have a lower encapsulation efficiency. It is also notable that 
when the droplets are smaller the interfacial area between the emulsion droplets and the 
external water phase is larger, hence the drug contained in the inner water phase has more 
area over which to diffuse. Moreover, the smaller the size, the shorter is the distance for the 
drug to reach the drop/particle surface.  
 
As shown for PLA and PLA/PLGA mixtures, when the osmotic pressure is high, water from 
the outer phase tends to enter the particles, leaving behind pores which provide exit routes for 
the inner phase once the particle has completely solidified [3,28]. At the same time, two other 
effects play an important role. Increasing salt concentration increases microsphere drug 
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loading by reducing drug aqueous solubility, and at the same time it may decrease 
microsphere drug loading by depressing organic solvent solubility in the aqueous phase [31]. 
However, in the case where all the organic solvent is removed the latter effect is one 
appropriate to the kinetics of the solidification process as, at equilibrium, all the solvent will be 
removed regardless of the solvent solubility. Other researchers on PLA have shown that the 
necessity to control the osmotic pressure is greater when membrane emulsification is used. It 
has been suggested that increasing encapsulation efficiency can be obtained by preparing 
the initial emulsion by using a membrane, rather than a homogeniser, and controlling the 
osmotic pressure [32]. A very comprehensive review of further developments in membrane 
based capsule and solid particle production, and factors influencing these appropriate to 
medical diagnostics and healthcare, has been published [33]. 
 
Conclusions 
 
For subcutaneous drug delivery biocompatible particles with diameters in a size range 
between 20 to 100 microns are required. These are of sufficient size to contain a reasonable 
amount of active ingredient, but not too big as to cause discomfort in administration and use. 
The production of particles in this size, and without the existence of material much smaller 
and bigger than these sizes, is challenging and often classification of the produced material is 
required to remove the under- and over-sized material. A more effective method would be to 
generate the required size, with minimal off-size material. Furthermore, encapsulation 
efficiencies should be as high as possible, so that the active ingredient is going to the product 
rather than to waste from the process. Membrane emulsification is an effective method for 
producing drop sizes, and hence particle sizes after solidification, in a controlled way. The 
membrane type used in this study is ideal for the production of subcutaneous drug delivery 
particles as it is possible to produce particles in the size range required and with 
encapsulation efficiencies (for a water in oil in water system) shown to be as high as 100%.  
 
The regular array of pores in the membranes studied had pore diameters of 20 and 40 
microns, producing a range of encapsulated particles with median diameters between 60 and 
140 microns. Membranes of this type are available with pore diameters down to 7 microns 
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and the resulting particle diameter is a significant function of pore diameter. In this study, and 
for the production of encapsulated PLGA particles, it was shown that for a salt ratio 
inner:outer water phases of 1:1 the 40 micron pore size gave a median diameter of 100 
microns and under the same operating conditions the 20 micron membrane gave a size of 60 
microns. The uniformity of these particles was very good, with calculated span values of 0.30, 
under conditions of 15% PLGA and a salt ratio of 1:1.  The same operating conditions gave 
encapsulation efficiencies close to 100%.  
 
During the solidification process the organic solvent transfers from the drops formed by the 
emulsification process to the external water phase and then to the water-air interface, where it 
then transfers to the air. As the organic solvent constitutes such a large amount of the organic 
phase, up to 95% by volume, the shrinkage of the drops as they solidify is substantial. 
Volume reductions of up to 75% are shown to be possible, for the particles using a 1:1 salt 
ratio between the inner and outer aqueous phases. As the shrinkage is less than the content 
of organic solvent it may be concluded that the PLGA encapsulated particles may have a 
structure swollen by water imbibition from the external phase. The minimum shrinkage 
between the drops formed and the solidified particles was 8% (volume reduction of 8% in 
Figure 7), despite the presence of 85% solvent which is removed during solidification. Hence 
the water imbibition would appear to be very significant with these particles. The conditions 
for minimum shrinkage existed when the salt ratio was such that there was a much higher salt 
concentration in the internal water phase in the W/O/W emulsion. Hence, there was a strong 
osmotic pressure driving the water from the external phase and in to the internal water phase. 
Despite this effect, the encapsulation efficiency was still approximately 100% for the 15% 
PLGA particles produced using the 40 micron pore size membrane.  
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Table 1  Overview of emulsion compositions 
 
1. PLGA particle production: 
Emulsion type: Oil (PLGA & DCM) in water; i.e. O/W emulsion 
Discontinuous phase: 5, 10, 15, 20, 30% PLGA, remaining material was DCM 
Continuous phase: 1% PVA dissolved in reverse osmosis water 
Emulsification 
condition: 
agitation speed: 
injection rate: 
membrane pore size: 
600 rpm stirrer speed 
0.5 ml/min 
40 µm 
 
2. PLGA encapsulated particle production: 
W/O/W Emulsion: 
Emulsion type: Water in Oil (PLGA & DCM) in water; i.e. W/O/W emulsion 
Inner water phase: 1000 ppm blue dextran 
40 g/l sodium chloride 
reverse osmosis water 
Oil phase: 5, 10, 15% PLGA, remaining material was DCM 
Outer water phase: 1% PVA dissolved in reverse osmosis water, together with: 
13, 26, 33, or 40 g/l sodium chloride and saturated with DCM 
Emulsification 
condition: 
Primary emulsion: 
Secondary 
emulsification: 
Agitation speed: 
Injection rate: 
Membrane pore size: 
By a mechanical homogeniser 
 
By membrane emulsification using: 
600, and 860 rpm stirrer speed 
0.5 ml/min 
40, 20 µm 
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Table 2  Solidification methods employed for the PLGA particles 
 
Method: Duration 
(hours) 
Evaporation area 
(cm2) 
Continuous 
phase added (ml) 
Agitation 
speed (rpm) 
A - Fast 2 150 1000 120 
B - Grad 24 150 450 120 
C - slow 24 50 - 120 
D - Very slow 72 1.7 - 120 
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Table 3 Different number size distribution spans obtained for PLGA 
encapsulated particles at different PLGA concentration, size and outer 
phase salt concentrations 
 
 
PLGA concentration 
 
(%) 
Ratio water phase salt 
concentration outer to inner  
Resulting Span of PLGA 
particles produced 
Pore size of membrane: 20 µm 
5  1 0.33 
5 0.83 0.35 
5 0.67 3.85 
5 0.33 3.66 
10 1 0.30 
10 0.83 0.32 
10 0.67 0.36 
10 0.33 0.34 
15 1 0.31 
15 0.83 0.30 
15 0.67 0.35 
15 0.33 0.35 
Pore size of membrane: 40 µm 
5  1 1.2 
5 0.83 0.51 
5 0.67 0.52 
5 0.33 0.63 
15 1 0.38 
15 0.83 0.46 
15 0.67 0.38 
15 0.33 0.40 
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